{"id":"neoadjuvant-chemotherapy-plus-concurrent-chemoradiotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"50-70%","effect":"Hair loss"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Neoadjuvant chemotherapy is administered before the main treatment to reduce the size of the tumor, while concurrent chemoradiotherapy involves the simultaneous use of chemotherapy and radiation therapy to further target and kill cancer cells.","oneSentence":"This treatment involves the use of chemotherapy and radiation therapy to target and kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:20.606Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced non-small cell lung cancer"},{"name":"Locally advanced esophageal cancer"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07447570","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-15","conditions":"Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody","enrollment":27},{"nctId":"NCT06208826","phase":"PHASE2","title":"A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-09-01","conditions":"Head and Neck Cancer","enrollment":268},{"nctId":"NCT05888402","phase":"PHASE2","title":"Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-20","conditions":"Local Advanced Non-small Cell Lung Cancer","enrollment":50},{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT03174275","phase":"PHASE2","title":"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2017-12-19","conditions":"Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer","enrollment":39},{"nctId":"NCT07423078","phase":"PHASE2","title":"Window of Opportunity in Preserving Laryngeal Function Trial","status":"NOT_YET_RECRUITING","sponsor":"Matthew Spector","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":87},{"nctId":"NCT07408635","phase":"PHASE2","title":"IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-01-07","conditions":"Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)","enrollment":43},{"nctId":"NCT05673772","phase":"PHASE2","title":"Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyungpook National University Hospital","startDate":"2020-10-23","conditions":"Rectal Cancer","enrollment":364},{"nctId":"NCT07400536","phase":"PHASE3","title":"A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-30","conditions":"Locally Advanced Cervical Carcinoma","enrollment":378},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07385664","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2026-01-28","conditions":"Resectable Esophageal Cancer","enrollment":66},{"nctId":"NCT07162506","phase":"PHASE2","title":"DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-01","conditions":"Esophageal Cancer","enrollment":120},{"nctId":"NCT05621707","phase":"PHASE2","title":"Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2022-11-02","conditions":"Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":50},{"nctId":"NCT07214987","phase":"PHASE2","title":"PDT For Induction Therapy For Head And Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-03-09","conditions":"Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":"Locally Advanced Rectal Carcinoma","enrollment":126},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT07103395","phase":"PHASE2","title":"A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT04028167","phase":"PHASE2","title":"Induction FLOT With CROSS CRT for Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-04-08","conditions":"Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction","enrollment":40},{"nctId":"NCT02213497","phase":"PHASE1","title":"Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2014-04","conditions":"Esophageal Cancer","enrollment":30},{"nctId":"NCT07317609","phase":"PHASE1","title":"Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT07248956","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-22","conditions":"Hypopharyngeal Carcinoma","enrollment":116},{"nctId":"NCT07291401","phase":"PHASE2","title":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","status":"NOT_YET_RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer Patients","enrollment":108},{"nctId":"NCT05340270","phase":"PHASE2","title":"PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangxi Medical University","startDate":"2022-07-15","conditions":"Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor","enrollment":150},{"nctId":"NCT04908696","phase":"","title":"Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-12-01","conditions":"Glottic Carcinoma, Supraglottic Carcinoma, Subglottic Carcinoma","enrollment":1000},{"nctId":"NCT07232654","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-11","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":30},{"nctId":"NCT04974047","phase":"PHASE2","title":"Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-17","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":70},{"nctId":"NCT05975307","phase":"PHASE2","title":"Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy","enrollment":71},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT05189730","phase":"PHASE2","title":"Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT06912074","phase":"PHASE2","title":"Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-05","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":134},{"nctId":"NCT03997435","phase":"PHASE2","title":"FOLFOXIRI With or Without Intensification for Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2019-09-10","conditions":"Rectal Cancer","enrollment":72},{"nctId":"NCT06281886","phase":"PHASE2","title":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":"Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity","enrollment":170},{"nctId":"NCT04209790","phase":"PHASE2","title":"Neoadjuvant Chemoradiation for Resectable Glioblastoma","status":"TERMINATED","sponsor":"Geisinger Clinic","startDate":"2020-04-01","conditions":"Glioblastoma, Surgery, High Grade Glioma","enrollment":2},{"nctId":"NCT07214142","phase":"PHASE2","title":"Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2025-10-01","conditions":"Rectal Cancer Patients","enrollment":30},{"nctId":"NCT07200141","phase":"PHASE2","title":"Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-10-01","conditions":"Locally Advanced Rectal Adenocarcinoma","enrollment":156},{"nctId":"NCT02505750","phase":"PHASE3","title":"Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2015-06-24","conditions":"Rectal Neoplasms","enrollment":148},{"nctId":"NCT07194616","phase":"NA","title":"Rectal Cancer CTC Trial","status":"RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2025-04-01","conditions":"Rectal Cancer Patients","enrollment":120},{"nctId":"NCT06448910","phase":"PHASE2","title":"Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC, Locally Advanced Lung Carcinoma","enrollment":41},{"nctId":"NCT07177443","phase":"PHASE3","title":"Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-25","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":456},{"nctId":"NCT06601309","phase":"PHASE2","title":"Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-07-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT05758389","phase":"PHASE2","title":"Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-04-01","conditions":"Head and Neck Tumors","enrollment":29},{"nctId":"NCT06770270","phase":"PHASE2","title":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Rectal Cancer","enrollment":68},{"nctId":"NCT06509568","phase":"PHASE2","title":"Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":92},{"nctId":"NCT02605265","phase":"PHASE3","title":"Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-10","conditions":"Locally Advanced Rectal Cancer","enrollment":356},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT06734702","phase":"PHASE3","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy","enrollment":497},{"nctId":"NCT01815853","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2013-06","conditions":"Gastric Cancer","enrollment":620},{"nctId":"NCT05272696","phase":"PHASE2","title":"Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-03-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT07041788","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2025-07-10","conditions":"Cancer","enrollment":25},{"nctId":"NCT07040098","phase":"PHASE2","title":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":228},{"nctId":"NCT07035808","phase":"PHASE2","title":"a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-01","conditions":"Cervical Cancer Stage IVA, Cervical Cancer Metastatic","enrollment":46},{"nctId":"NCT02730546","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-06-24","conditions":"Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7","enrollment":31},{"nctId":"NCT07026422","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-05-30","conditions":"Rectal Malignant Neoplasms","enrollment":54},{"nctId":"NCT07020247","phase":"PHASE3","title":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-19","conditions":"Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy","enrollment":184},{"nctId":"NCT05357846","phase":"PHASE3","title":"PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-01","conditions":"Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":422},{"nctId":"NCT06009861","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University Hospital of Stomatology","startDate":"2023-06-27","conditions":"Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma","enrollment":110},{"nctId":"NCT06990178","phase":"NA","title":"Adaptive Neoadjuvant Therapy for Esophageal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2028-03-01","conditions":"Esophageal Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT00405405","phase":"PHASE1","title":"Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-12","conditions":"Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer","enrollment":13},{"nctId":"NCT06924619","phase":"PHASE2","title":"Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-10-30","conditions":"Locally Advanced Thymoma","enrollment":178},{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT06916117","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-05","conditions":"Locally Advanced Cervical Cancer","enrollment":30},{"nctId":"NCT04025541","phase":"NA","title":"Analysis of Circulating Tumor Markers in Blood","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2018-05-29","conditions":"Cancer, Breast Cancer, Sarcoma","enrollment":992},{"nctId":"NCT02305654","phase":"PHASE3","title":"International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-05-12","conditions":"Squamous Cell Carcinoma of the Penis, Usual Type","enrollment":200},{"nctId":"NCT06715501","phase":"NA","title":"Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2024-12-01","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages","enrollment":20},{"nctId":"NCT06288360","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-09-12","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative","enrollment":40},{"nctId":"NCT06712888","phase":"PHASE3","title":"Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-02-17","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":466},{"nctId":"NCT06210971","phase":"PHASE2","title":"Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-02-01","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT06246344","phase":"","title":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-12-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT02688712","phase":"PHASE2","title":"ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2016-03-24","conditions":"Rectal Adenocarcinoma","enrollment":50},{"nctId":"NCT06863831","phase":"NA","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-22","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":536},{"nctId":"NCT04016675","phase":"NA","title":"Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2019-09-01","conditions":"Malignant Tumor of Lacrimal Drainage Structure","enrollment":94},{"nctId":"NCT00544414","phase":"PHASE2","title":"Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-06-07","conditions":"Head and Neck Cancer","enrollment":31},{"nctId":"NCT06814067","phase":"PHASE2","title":"Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-02-10","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":80},{"nctId":"NCT06781112","phase":"PHASE2","title":"A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Weiwei Zhang","startDate":"2025-01-20","conditions":"TPF, Immunotherapy, Nasopharyngeal Carcinoma","enrollment":35},{"nctId":"NCT06768307","phase":"PHASE2","title":"Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02","conditions":"SCLC, Extensive Stage, Immunotherapy, Chemotherapy","enrollment":60},{"nctId":"NCT04375605","phase":"PHASE3","title":"Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsmedizin Mannheim","startDate":"2020-06-03","conditions":"Gastroesophageal Junction Adenocarcinoma","enrollment":342},{"nctId":"NCT06762158","phase":"NA","title":"NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-10-30","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":50},{"nctId":"NCT05292027","phase":"NA","title":"Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2022-03-26","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT06752382","phase":"PHASE2","title":"Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-12-31","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":58},{"nctId":"NCT02573493","phase":"PHASE2","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04-13","conditions":"Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck","enrollment":96},{"nctId":"NCT06430658","phase":"PHASE2","title":"Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-01","conditions":"Esophagus Cancer","enrollment":90},{"nctId":"NCT05601505","phase":"PHASE2","title":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-02-03","conditions":"Locally Advanced Rectal Carcinoma, Circulating Tumor DNA","enrollment":470},{"nctId":"NCT06714084","phase":"NA","title":"CNCMT：a Multi-center, Prospective, Single-arm Study","status":"ENROLLING_BY_INVITATION","sponsor":"Hubei Cancer Hospital","startDate":"2024-10-08","conditions":"Locally Advanced Cervical Cancer, PD1, CTLA4","enrollment":20},{"nctId":"NCT06444009","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Lei Liu","startDate":"2024-07-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT05370144","phase":"NA","title":"A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-02-08","conditions":"Esophageal Cancer","enrollment":42},{"nctId":"NCT03381651","phase":"NA","title":"Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-02-22","conditions":"Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery","enrollment":147},{"nctId":"NCT06667622","phase":"PHASE2","title":"Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-29","conditions":"Chemoradiotherapy","enrollment":40},{"nctId":"NCT05468242","phase":"PHASE2","title":"Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Stage III Non-small Cell Lung Cancer","enrollment":116},{"nctId":"NCT06288373","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-04-22","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy","enrollment":440},{"nctId":"NCT05099809","phase":"","title":"Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia in Locally Advanced Cancers","status":"RECRUITING","sponsor":"Mahatma Gandhi Institute of Medical Sciences","startDate":"2021-10-18","conditions":"Locally Advanced Malignant Neoplasm","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neoadjuvant Chemotherapy Followed by CCRT"],"phase":"phase_3","status":"active","brandName":"neoadjuvant chemotherapy plus concurrent chemoradiotherapy","genericName":"neoadjuvant chemotherapy plus concurrent chemoradiotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This treatment involves the use of chemotherapy and radiation therapy to target and kill cancer cells. Used for Locally advanced non-small cell lung cancer, Locally advanced esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}